March 25th 2021
The fixed-dose combination of relatlimab plus nivolumab was found to improve progression-free survival over nivolumab alone in patients with previously untreated metastatic or unresectable melanoma, meeting the primary end point of the phase 2/3 RELATIVITY-047 trial.
March 19th 2021
Geoffrey T. Gibney, MD, discusses the potential utility of fixed-duration immunotherapy in melanoma.
February 9th 2021
February 9, 2021 - The FDA has approved cemiplimab-rwlc as the first immunotherapy for use in patients with advanced basal cell carcinoma that has previously been treated with a hedgehog pathway inhibitor (HHI) or for whom a HHI is not appropriate.
January 25th 2021
January 25, 2021 - The FDA has granted toripalimab a fast track designation for use in the frontline treatment of patients with mucosal melanoma.
January 13th 2021
Ryan Sullivan, MD, discusses treatment sequencing with targeted therapy and immunotherapy in melanoma.
January 11th 2021
Mario Sznol, MD, Yale Cancer Center, discusses the multidisciplinary management of toxicities associated with immunotherapy in patients with melanoma.
January 11th 2021
January 11, 2021 — The FDA has granted an orphan drug designation to the novel intratumoral immunotherapy agent PVSRIPO for the treatment of patients with advanced melanoma, specifically those with stage IIIB-IV disease.
January 7th 2021
Mario Sznol, MD, discusses toxicities associated with immunotherapy in patients with melanoma.
December 14th 2020
Mario Sznol, MD, discusses the critical importance of being aware of the immune-related toxicities that could arise when treating patients with cancer, along with the best ways to manage them.
December 7th 2020
In our exclusive interview, Caroline Robert, MD, PhD, discusses her groundbreaking work on clinical trials evaluating anti–CTLA-4 and anti–PD-1 antibodies in advanced melanoma, her experiences as a researcher in France and the United States, her love of traveling, and next steps for the field.